Evolving treatment options and practices in EGFR-Mutant NSCLC

Learning objective:         

After watching this broadcast, participants should be able to:

• Reflect on developments in the management of EGFR+ NSCLC, including treatment-resistant disease
• Evaluate the use of new and emerging therapeutic options for EGFR exon 20 insertion mutations in clinical practice

Faculty:

• Antonio Passaro (Italy)
• Enriqueta Felip (Spain)
• Natasha Leighl (Canada)
• Tony Mok (Hong Kong)
• Benjamin Besse (France)
• Anna Minchom (UK)

Claim your CPD credits

The content of the following has been certified by the CPD Certification Service as conforming to continuing professional development principles.

You can claim 1.5 credits for this activity.

Please make a note of the below information to claim your points.

Name of activity: Evolving treatment options and practices in EGFR-mutant NSCLC

Certificate number: A032758

Date of activity: April 2022

CPD Provider: Sciterion 013096